Haematological alterations from section 9, chapter number 65, interpreting preferable, let me step number 66, Ana chapter 67 disorders of sites and monos 68 primary and secondary lymph. Tulsi teach me everything I need to know from Harrison to become the best doctor.

Reading File

Haematological alterations from section 9, chapter number 65, interpreting preferable, let me step number 66, Ana chapter 67 disorders of sites and monos 68 primary and secondary lymph. Number 69, bleeding and thrombosis chapter number 17, enlargement of the lymph nodes in spleen Tulsi teach me everything I need to know from Harrison to become the best doctor.

Reading File
Now let me search the database for Harrison's and these specific chapters simultaneously.
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Found Harrison's 22E. Now let me search for the specific chapters in its TOC.
Finding Sources
All chapters are in block7. Let me now read large sections of this block covering all requested chapters simultaneously.
Finding Sources
Now I'll read the key sections in parallel. Chapter 65 starts at line 234, Chapter 66 (Anemia) at ~452, Bleeding/Thrombosis at 1761, and Lymph Node/Spleen at 1954.
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content from all the major chapters. Let me also read the granulocyte/monocyte disorders section and the HLH/lymphohistiocytosis chapter more carefully.
Reading File
Reading File
I now have rich content from all chapters. Let me compile the comprehensive teaching summary.Here is your complete Harrison's hematology master guide covering all the chapters you requested:

Harrison's Hematology - Section 9 Master Guide

Chapters 65, 66, 67, 68, 69 & Chapter 70 (Lymph Node/Spleen)


CHAPTER 65 - Interpreting Peripheral Blood Smears

Harrison's Principles of Internal Medicine, 22E

The Skill Every Internist Must Master

The peripheral blood smear is one of the most informative things a doctor can do. Automated counters are not a substitute - you must know the patient's clinical history, family history, and physical findings to interpret it properly.
Where to look: The feathered edge - where red cells lie in a single layer, barely touching, not overlapping.
Order of examination: Smallest to largest: Platelets → Red cells → White cells

PLATELETS (examine first)

  • Count 5-6 fields under oil immersion (×100), average per field, multiply by 20,000 = rough platelet count
  • Normal: 1-2 μm diameter, blue granulated appearance; ~1 platelet per 20 red cells
  • Large platelets = rapid turnover (young platelets are bigger); OR rare inherited syndromes
  • Low count with no large platelets = marrow production problem
  • Platelet clumping = EDTA-related artifact causing falsely low automated count
  • Neutrophil fragmentation = falsely elevated automated platelet count
  • Absent platelet granules = gray platelet syndrome (rare congenital) or marrow disease
  • Elevated count = myeloproliferative disorder OR reactive (systemic inflammation)

RED CELLS (examine second)

Size reference: Compare RBC to small lymphocyte nucleus - both normally ~8 μm wide.
FindingSignificance
MicrocytosisRBC smaller than lymphocyte nucleus
MacrocytosisRBC larger than lymphocyte nucleus (also more oval = macro-ovalocytes)
AnisocytosisWide variation in size
PoikilocytosisWide variation in shape
RDW (red cell distribution width)Normal 11-14%; rises to 15-18% with morphologic anisocytosis
Key RDW formula: RDW = (SD of MCV ÷ mean MCV) × 100
Clinical use of RDW in microcytic anemia:
  • Iron deficiency: RDW elevated (mixed-size cells, early iron-deficient cells are small)
  • Thalassemia: RDW usually normal (uniformly small cells)

Specific RBC Morphology

Abnormal CellDiagnosis/Significance
Burr cells (echinocytes)Uremia, artifact
ElliptocytesHereditary elliptocytosis
Howell-Jolly bodiesAsplenia, splenic dysfunction
Hypochromia/microcytosisIron deficiency, thalassemia
Macro-ovalocytesB12/folate deficiency (megaloblastic anemia)
Nucleated RBCsMyelophthisic process, severe hemolysis, marrow infiltration
SchistocytesMicroangiopathic hemolytic anemia (TTP, HUS, DIC, mechanical heart valve)
Sickle cellsSickle cell disease
SpherocytesHereditary spherocytosis, autoimmune hemolytic anemia
Target cellsLiver disease, thalassemia, hemoglobin C disease
Tear-drop cells (dacrocytes)Marrow infiltration (myelophthisic anemia)
AcanthocytesAbetalipoproteinemia, severe liver disease
Basophilic stipplingLead poisoning, thalassemia, sideroblastic anemia
RouleauxHypergammaglobulinemia, multiple myeloma

WHITE CELLS (examine third)

  • Normal differential: Neutrophils 50-70%, Lymphocytes 20-40%, Monocytes 2-8%
  • Left shift = increased band forms (immature neutrophils) - sign of acute infection/inflammation
  • Hypersegmented neutrophils (>5 lobes) = B12/folate deficiency
  • Toxic granulation + Döhle bodies = severe bacterial infection, sepsis
  • Pelger-Hüet anomaly = bilobed neutrophils; genetic (LBR mutation) or acquired (MDS)
  • Auer rods = pathognomonic for AML (myeloid blasts)
  • Atypical lymphocytes = EBV (infectious mononucleosis), CMV, viral infections

CHAPTER 66 - Anemia and Polycythemia

Epidemiology

Anemia affects almost 2 billion people worldwide - one of the most common medical problems.

Normal Red Cell Production

  • Hematopoietic stem cell → regulated by transcription factors GATA-1 and FOG-1 for erythroid/megakaryocytic lineage
  • EPO (erythropoietin) = primary regulatory hormone from kidney; absence → apoptosis of erythroid progenitors
  • First morphologically recognizable erythroid precursor = pronormoblast → 4-5 divisions → 16-32 mature RBCs
  • Normal RBC: 8 μm, anucleate, biconcave disc; survives 100-120 days
  • Daily replacement: 0.8-1% of all circulating RBCs
EPO production is regulated by tissue oxygen tension (kidney senses hypoxia → increases EPO).

Classification of Anemia (3 mechanisms)

1. Hypoproliferative Anemia (most common - 75% of all anemias)

  • Inadequate EPO production OR marrow unable to respond
  • Causes: Iron deficiency, inflammation (anemia of chronic disease), renal disease (low EPO), marrow suppression

2. Maturation Defect Anemia

  • Nuclear maturation defect (DNA synthesis impaired): B12/folate deficiency → megaloblastic anemia, macrocytosis, hypersegmented neutrophils
  • Cytoplasmic maturation defect (hemoglobin synthesis impaired): Iron deficiency, thalassemia → microcytic, hypochromic

3. Blood Loss / Hemolysis

  • Blood loss or accelerated destruction → reticulocytosis (marrow responding)
  • Intravascular hemolysis: hemoglobinuria, low haptoglobin, elevated LDH
  • Extravascular hemolysis: spleen destroys RBCs, elevated indirect bilirubin

Key Laboratory Tests

TestNormal ValuesClinical Use
Serum iron9-27 μmol/L (50-150 μg/dL)Iron availability
TIBC (total iron binding capacity)54-64 μmol/L (300-360 μg/dL)Surrogate for transferrin
Transferrin saturation25-50%(Serum iron ÷ TIBC) × 100
Serum ferritinMales ~100 μg/L; Females ~30 μg/LIron stores; also acute phase reactant
Ferritin <30 μg/L-Iron stores depleted
Ferritin >200 μg/L-At least some stores present
Reticulocyte count1-2%Marrow response to anemia

Specific Causes

Iron Deficiency:
  • Most common nutritional deficiency worldwide
  • Most common in premenopausal women (menstrual losses)
  • Classic finding: microcytic, hypochromic anemia
  • Early iron deficiency may not show microcytosis
  • Low ferritin + low transferrin saturation
Vitamin B12 Deficiency:
  • Required for RBC DNA synthesis → deficiency = impaired DNA synthesis
  • Classic finding: macrocytosis + hypersegmented neutrophils + remarkably hypercellular marrow with large abnormal precursors
  • Neurologic manifestations (subacute combined degeneration)
Folate Deficiency:
  • Same hematologic picture as B12 (grouped as megaloblastic anemia)
  • No neurological manifestations
  • Rare in countries supplementing flour with folate
  • See in poor diet, severe malabsorption
Copper Deficiency:
  • Associated with neurologic disease AND neutropenia
Vitamin C Deficiency:
  • Severe anemia + clinical findings of scurvy
Marrow Replacement (Myelophthisic Anemia):
  • Infections (histoplasmosis, TB) or neoplasms (prostate cancer metastases, multiple myeloma) crowd out hematopoietic elements
  • Blood smear: nucleated RBCs + tear-drop cells + immature WBCs = leukoerythroblastic picture
  • Mandates bone marrow biopsy
Renal Anemia:
  • Kidney = primary source of EPO → renal disease → reduced EPO → hypoproliferative anemia
  • Normocytic, normochromic; low reticulocyte count

Polycythemia

  • Relative polycythemia = decreased plasma volume (dehydration, "stress polycythemia")
  • Absolute polycythemia = increased RBC mass
    • Primary: Polycythemia vera (JAK2 V617F mutation; low EPO)
    • Secondary: High EPO - appropriate (altitude, COPD, sleep apnea) or inappropriate (renal cell carcinoma, hepatocellular carcinoma producing EPO)

CHAPTER 67 - Disorders of Granulocytes and Monocytes

Granulopoiesis

  • Myeloid stem cell → committed progenitor → myeloblast → promyelocyte → myelocyte → metamyelocyte → band → neutrophil
  • G-CSF (granulocyte colony-stimulating factor) is the key cytokine
  • Bone marrow storage pool = 10-15 times the circulating neutrophil mass; released in infection/stress

Neutrophil Function

  1. Margination - neutrophils loosely adhere to vascular endothelium (selectins)
  2. Rolling - along endothelium via selectins
  3. Adhesion - firm adhesion via integrins (LFA-1/Mac-1 binding ICAM-1)
  4. Diapedesis - migration through vessel wall
  5. Chemotaxis - movement toward bacteria (fMLF, C5a, IL-8, leukotriene B4)
  6. Phagocytosis - engulf opsonized bacteria (IgG + complement)
  7. Killing - oxidative burst (NADPH oxidase/NOX2 → superoxide → H2O2 → myeloperoxidase + Cl⁻ → hypochlorous acid/bleach); non-oxidative (defensins, elastase, lysozyme, lactoferrin)
Neutrophil Extracellular Traps (NETs): DNA scaffolds decorated with granule proteins (proteases, antimicrobial peptides) - immobilize invading microorganisms.
After phagocytosis: neutrophils die in 1-4 days in tissues; G-CSF and IFN-γ prolong their life span.

Neutropenia

Definition: ANC (absolute neutrophil count) < 1800/μL
  • Mild: 1000-1800/μL
  • Moderate: 500-1000/μL
  • Severe: <500/μL (risk of serious infection rises sharply)
  • Profound: <100/μL (Kostmann's syndrome level)

Hereditary Neutropenias

SyndromeGeneKey Features
Kostmann syndromeHAX-1Neutrophils <100/μL; anti-apoptosis gene mutation; often fatal
Severe chronic neutropeniaELANE (neutrophil elastase)ANC 300-1500/μL
Cyclic hematopoiesisELANECyclic neutropenia every ~21 days
Cartilage-hair hypoplasiaRMRPShort stature + neutropenia
Shwachman-Diamond syndromeSBDSPancreatic exocrine insufficiency + neutropenia
WHIM syndromeCXCR4Warts, hypogammaglobulinemia, infections, myelokathexis
Reticular dysgenesisAK2Absence of both myeloid AND lymphoid cells
Mutations in G-CSF receptor in severe congenital neutropenia are linked to leukemia development.
Felty syndrome: Triad of rheumatoid arthritis + splenomegaly + neutropenia. Antibodies shorten neutrophil life; large granular lymphocytes attack marrow precursors. Splenectomy may help.

Neutrophilia

Causes:
  • Infection (most important acute cause) - increased production + marrow release
  • Glucocorticoids - mobilize marginated pool from blood vessel walls
  • Epinephrine/exercise/stress - demargination (doubles count in minutes)
  • Cigarette smoking - mild chronic elevation
  • Chronic inflammation
  • Myeloproliferative diseases
Leukemoid reaction: WBC ≥30,000-50,000/μL with mature, non-clonal neutrophils (vs leukemia where cells are clonal and often immature).

Neutrophil Function Defects

Chronic Granulomatous Disease (CGD)

  • Defect in NADPH oxidase (NOX2) → cannot generate oxidative burst
  • X-linked (most common) or autosomal recessive
  • Recurrent infections with catalase-positive organisms: Staph aureus, Aspergillus, Serratia, Nocardia, Burkholderia
  • Granuloma formation (try to wall off what they can't kill)
  • Diagnosis: DHR (dihydrorhodamine) flow cytometry or nitroblue tetrazolium (NBT) test

Leukocyte Adhesion Deficiency (LAD)

  • Type I: CD18 (beta-2 integrin) deficiency → neutrophils can't adhere/migrate
  • Hallmark: Extremely high WBC count with no pus despite severe infection; delayed umbilical cord separation
  • Diagnosis: flow cytometry for CD11b/CD18

Chediak-Higashi Syndrome

  • Defect in LYST (lysosomal trafficking regulator) gene
  • Giant lysosomes in neutrophils, monocytes, lymphocytes on smear
  • Partial albinism + recurrent infections + peripheral neuropathy
  • Accelerated phase = HLH-like picture

Myeloperoxidase (MPO) Deficiency

  • Most common inherited neutrophil disorder
  • Usually asymptomatic; mild susceptibility to Candida especially with diabetes

Eosinophilia and Basophilia

Eosinophilia (>500/μL):
  • Allergic diseases (asthma, hay fever, eczema)
  • Drug reactions
  • Parasitic infections (especially tissue-invasive: Toxocara, Strongyloides, Ascaris)
  • Hypereosinophilic syndrome (>1500/μL for >6 months with organ damage)
  • Malignancy (Hodgkin lymphoma, T-cell lymphoma)
  • Adrenal insufficiency (Addison's - classic boards point)
Basophilia:
  • Myeloproliferative disorders (especially CML - basophilia is a hallmark)
  • Allergic reactions, hypothyroidism

Monocytes and Macrophages

  • Monocytes circulate 1-3 days then enter tissues → become macrophages
  • Monocytosis: TB, fungal infections, monocytic leukemia, inflammatory bowel disease, recovery from neutropenia
  • Macrophages are central to granuloma formation (TB, sarcoidosis, Crohn's)

CHAPTER 68 - Primary and Secondary Hemophagocytic Lymphohistiocytosis (HLH)

What is HLH?

A highly life-threatening condition of massive, uncontrolled inflammation (hyperinflammation). Primary (genetic) and secondary (acquired) forms exist. All forms share a convergent phenotype - sepsis-like inflammation → multiple organ failure → death if untreated.
  • Primary HLH: Mostly children; Mendelian (genetic)
  • Secondary HLH: Far more common in adults; triggered by infections, malignancies, autoimmune diseases
Macrophage Activation Syndrome (MAS or MAS-HLH) = HLH triggered by autoimmune conditions (SoJIA, adult-onset Still's disease, SLE)

Primary HLH - Genetic Forms

All primary HLH involves defects in lymphocyte cytotoxicity - cytotoxic T-cells and NK cells cannot effectively kill target cells, leading to prolonged immune activation.
GeneSyndrome
PRF1FHL2 - Familial HLH type 2 (perforin deficiency - most common)
UNC13DFHL3
STX11FHL4
STXBP2FHL5
SH2D1AXLP1 (X-linked lymphoproliferative disease type 1)
RAB27AGriscelli syndrome type 2
LYSTChediak-Higashi syndrome
BIRC4XLP2 (inflammasome activation defect)

Secondary HLH Triggers

  • Infection-associated: EBV (most common viral trigger), CMV, HIV, bacteria, parasites, fungi
  • Malignancy-associated: T-cell lymphoma, NK-cell lymphoma (most common), B-cell lymphoma
  • Autoimmune-associated (MAS): SoJIA, adult-onset Still's disease, SLE, vasculitis
  • Transplant-associated: Post-HSCT, post-CAR-T cell therapy

HScore - Diagnostic Scoring

(Probability of HLH based on clinical features - score >169 = >93% probability of HLH)

HLH-2004 Diagnostic Criteria (≥5/8 required)

  1. Fever ≥38.5°C
  2. Splenomegaly
  3. Cytopenias in ≥2 cell lines (Hb <90 g/L; platelets <100×10⁹/L; neutrophils <1×10⁹/L)
  4. Hypertriglyceridemia (fasting triglycerides ≥3 mmol/L) AND/OR hypofibrinogenemia (fibrinogen ≤1.5 g/L)
  5. Hemophagocytosis in bone marrow, spleen, or lymph nodes
  6. Low/absent NK-cell activity
  7. Ferritin ≥500 μg/L (very high ferritin, often >10,000 is highly suggestive)
  8. Elevated soluble CD25 (sIL-2 receptor) ≥2400 U/mL

Treatment

  • Primary HLH: HLH-94/HLH-2004 protocol (dexamethasone + etoposide); followed by allogeneic HSCT (only cure)
  • MAS-HLH: Treat underlying autoimmune disease + cyclosporine + anakinra (IL-1 blockade)
  • Secondary HLH (infection-associated): Treat underlying trigger + immunosuppression if needed
Key point: Ferritin >10,000 μg/L has very high specificity for HLH. Extremely high ferritin + fever + splenomegaly + cytopenias = think HLH immediately.

CHAPTER 69 - Bleeding and Thrombosis

Clinical Approach to Bleeding Disorders

The most important predictor of bleeding risk = history of bleeding
Key history questions:
  1. Spontaneous vs. trauma/surgery-induced bleeding?
  2. Mucosal bleeding (epistaxis, heavy periods, gum bleeding) = platelet/VWD disorder (primary hemostasis)
  3. Hemarthroses (joint bleeds) = clotting factor deficiency (factor VIII, IX) = secondary hemostasis
  4. Family history (inherited vs acquired)
  5. Medications (aspirin, NSAIDs, anticoagulants, supplements)
ISTH Bleeding Assessment Tool - validated tool to predict inherited bleeding disorders, especially type 1 VWD.

Primary Hemostasis (Platelet Plug Formation)

Step 1 - Vascular injury → subendothelial collagen exposed + endothelin release + vasoconstriction
Step 2 - Platelet adhesion → von Willebrand factor (VWF) bridges collagen to platelet GPIb-IX-V
Step 3 - Platelet activation → shape change, granule release (ADP, TXA2, serotonin)
Step 4 - Platelet aggregation → GPIIb/IIIa binds fibrinogen → platelet-platelet bridges

Disorders of Primary Hemostasis (Platelet Plug)

Defects of Platelet Adhesion:
  • Von Willebrand Disease (VWD) - most common inherited bleeding disorder; VWF deficiency/dysfunction
  • Bernard-Soulier syndrome - absent/dysfunctional GPIb-IX-V; giant platelets + thrombocytopenia
Defects of Platelet Aggregation:
  • Glanzmann's thrombasthenia - absent/dysfunctional GPIIb/IIIa; normal platelet count but no aggregation
  • Afibrinogenemia - no fibrinogen to bridge platelets
Defects of Platelet Secretion:
  • Decreased cyclooxygenase activity (aspirin, NSAIDs)
  • Storage pool diseases (dense granule deficiency)

Secondary Hemostasis (Coagulation Cascade)

Extrinsic pathway: Tissue factor + Factor VII → VIIa → activates X → Xa
Intrinsic pathway: XII → XI → IX → VIIIa + IXa → activates X
Common pathway: Xa + Va → prothrombin (II) → thrombin (IIa) → fibrinogen → fibrin

Coagulation Tests

TestPathwayFactors Detected
PT (prothrombin time)/INRExtrinsic + commonVII, X, V, II, fibrinogen
aPTT (activated partial thromboplastin time)Intrinsic + commonXII, XI, IX, VIII, X, V, II, fibrinogen
Thrombin timeFibrinogen → fibrinFibrinogen, thrombin inhibitors
Bleeding time / PFA-100Primary hemostasisPlatelet function, VWF

Important Clotting Factor Disorders

DisorderFactorKey Features
Hemophilia AFactor VIIIX-linked; hemarthroses; aPTT prolonged, PT normal
Hemophilia B (Christmas disease)Factor IXX-linked; same clinical picture as A
VWD Type 1VWF (partial quantitative)Mucosal bleeding; most common
VWD Type 2VWF (qualitative)Subtypes 2A, 2B, 2M, 2N
VWD Type 3VWF (absent)Severe; also low factor VIII
DICMultipleAll factors consumed; elevated D-dimer, low fibrinogen

Thrombosis

History of thrombosis key points:
  • Arterial thrombosis = platelet-rich ("white clot") - often from atherosclerosis, atrial fibrillation
  • Venous thrombosis = fibrin-rich ("red clot") - stasis, hypercoagulability

Virchow's Triad (DVT/PE pathophysiology)

  1. Stasis (immobility, heart failure)
  2. Endothelial injury (surgery, trauma, indwelling catheters)
  3. Hypercoagulability (inherited or acquired)

Inherited Thrombophilias

ConditionDefectRisk
Factor V LeidenResistance to protein CMost common inherited thrombophilia
Prothrombin G20210AElevated prothrombin2nd most common
Protein C deficiencyReduced anticoagulantNeonatal purpura fulminans (homozygous)
Protein S deficiencyReduced anticoagulant co-factorSimilar to Protein C deficiency
Antithrombin deficiencyReduced heparin co-factorHeparin resistance
MTHFR mutationHyperhomocysteinemiaWeak risk factor

Acquired Thrombophilias

  • Antiphospholipid syndrome (APS): Lupus anticoagulant + anticardiolipin antibodies + anti-β2GP1; paradoxically prolonged aPTT but causes THROMBOSIS; recurrent pregnancy loss
  • Myeloproliferative neoplasms: Polycythemia vera, essential thrombocythemia
  • Malignancy: Trousseau syndrome (migratory thrombophlebitis)
  • Oral contraceptives, HRT
  • Prolonged immobility, pregnancy, obesity

CHAPTER 70 - Enlargement of Lymph Nodes and Spleen

Lymphadenopathy

Epidemiology

  • 2/3 of patients with lymphadenopathy in primary care have nonspecific/viral upper respiratory causes
  • <1% have malignancy in primary care settings
  • In referral settings: 84% benign; 16% malignant (lymphoma or metastatic adenocarcinoma)
  • Of benign: 63% nonspecific/reactive; rest = infectious mono, toxoplasmosis, TB most commonly

Normal Nodes (do NOT investigate further)

  • Submandibular nodes <1 cm in children/young adults - normal
  • Inguinal nodes up to 2 cm in healthy adults - normal
  • Soft, flat, non-tender

Clinical Assessment Framework

History:
  • Age (children/young adults = benign viral; >50 years = malignancy rises)
  • Symptoms: sore throat, cough, fever, night sweats, fatigue, weight loss
  • Exposures: pets (cat-scratch disease, toxoplasmosis), sexual history (HIV, syphilis), TB exposure
  • Occupation
  • Drugs: phenytoin (diphenylhydantoin) causes lymphadenopathy
  • Tobacco history + cervical nodes → malignancy must be excluded
Physical exam:
  • Localized or generalized (≥3 non-contiguous regions)
  • Size, texture (soft/hard/rubbery), tenderness, fluctuance
  • Overlying skin changes
  • Splenomegaly
  • Other organomegaly

Node Characteristics Guide

FeatureSuggests
Soft, tender, mobileReactive/infectious
Hard, fixed, non-tenderMalignancy
Rubbery, mattedLymphoma
FluctuantAbscess, TB lymphadenitis
GeneralizedSystemic disease (HIV, EBV, SLE, lymphoma)
Supraclavicular node (Virchow's node)Intra-abdominal or thoracic malignancy

Differential Diagnosis of Lymphadenopathy

Infectious:
  • Viral: EBV (mono), CMV, HIV, hepatitis, rubella, adenovirus
  • Bacterial: Streptococcal, TB, cat-scratch disease (Bartonella), brucellosis, syphilis
  • Fungal: Histoplasmosis, coccidioidomycosis
  • Parasitic: Toxoplasmosis
Immunologic:
  • SLE, rheumatoid arthritis (Felty), serum sickness, drug reaction (phenytoin, allopurinol, INH)
Malignant:
  • Hodgkin lymphoma (Reed-Sternberg cells)
  • Non-Hodgkin lymphoma
  • Leukemia (CLL, ALL)
  • Metastatic carcinoma (breast, lung, melanoma, head/neck)
Other:
  • Sarcoidosis
  • Castleman disease
  • Kikuchi disease (necrotizing lymphadenitis - young Asian women, self-limiting)
  • Amyloidosis

When to Biopsy?

  • Nodes >2 cm persisting >4-6 weeks without explanation
  • Hard, fixed nodes
  • Supraclavicular adenopathy (always biopsy - very high malignancy risk)
  • Generalized adenopathy with constitutional symptoms ("B symptoms": fever, night sweats, weight loss >10%)
  • Progressive growth
  • Abnormal CBC or LDH

Splenomegaly

Functions of the Spleen

  1. Filtration - removes senescent/abnormal RBCs; removes encapsulated bacteria (asplenic patients at risk for overwhelming sepsis from Pneumococcus, Meningococcus, H. influenzae)
  2. Immune surveillance - T and B cell areas, immunoglobulin production
  3. Storage - platelets, monocytes
  4. Hematopoiesis - extramedullary hematopoiesis when marrow fails

Causes of Splenomegaly

Massive splenomegaly (spleen extends beyond umbilicus):
  • Chronic myeloid leukemia (CML)
  • Myelofibrosis
  • Visceral leishmaniasis (kala-azar)
  • Malaria (hyperreactive malarial splenomegaly)
  • Thalassemia major/intermedia
Moderate:
  • Portal hypertension (cirrhosis, schistosomiasis)
  • Lymphoma, leukemia
  • Storage diseases (Gaucher's, Niemann-Pick)
  • Autoimmune hemolytic anemia
Mild:
  • Infectious mononucleosis (EBV)
  • Bacterial endocarditis
  • Viral hepatitis
  • Rheumatoid arthritis, SLE
  • Systemic infections

Hypersplenism

  • Splenomegaly → sequestration and destruction of blood cells
  • Pancytopenia (low WBC, RBC, platelets) with hypercellular bone marrow
  • Treat underlying cause; splenectomy as last resort

Assessment

  • Physical exam: Normally the spleen must enlarge 2-3x before palpable
  • Best imaging: ultrasound or CT (spleen >12 cm = splenomegaly)
  • Nuclear scan: most sensitive for function

MASTER CLINICAL PEARLS - High-Yield Exam Points

  1. RDW elevated + microcytosis = iron deficiency; RDW normal + microcytosis = thalassemia
  2. Auer rods = AML (pathognomonic)
  3. Hypersegmented neutrophils = B12/folate deficiency
  4. Pelger-Hüet anomaly = bilobed neutrophils (inherited LBR mutation or acquired in MDS)
  5. Hemarthroses = factor deficiency (hemophilia); Mucosal bleeding = platelet/VWD problem
  6. Prolonged aPTT, normal PT = intrinsic pathway defect (hemophilia A/B, VWD, lupus anticoagulant)
  7. Prolonged PT, normal aPTT = extrinsic pathway (factor VII deficiency, early liver disease, warfarin)
  8. Both PT + aPTT prolonged = common pathway defect, DIC, severe liver disease, supratherapeutic anticoagulation
  9. APS = prolonged aPTT but causes CLOTS not bleeding; recurrent pregnancy loss
  10. Factor V Leiden = most common inherited thrombophilia; activated protein C resistance
  11. Ferritin >10,000 = think HLH immediately (along with fever, splenomegaly, cytopenias)
  12. Felty syndrome = RA + splenomegaly + neutropenia
  13. CGD = recurrent catalase-positive organism infections; NBT test negative (no oxidative burst)
  14. LAD type I = very high WBC + no pus + delayed cord separation
  15. Kostmann syndrome = neutrophils <100/μL; HAX-1 mutation; often fatal without G-CSF/HSCT
  16. Supraclavicular lymphadenopathy = always workup aggressively; highest malignancy risk of any location
  17. Massive splenomegaly = think CML, myelofibrosis, kala-azar, thalassemia, malaria
  18. Asplenic patients = at risk for overwhelming sepsis from encapsulated organisms; vaccinate against Pneumococcus, Meningococcus, H. influenzae
  19. Pronormoblast = first morphologically recognizable erythroid precursor
  20. EPO from kidney = absence causes apoptosis of erythroid progenitors; renal failure → normocytic anemia

*All content from Harrison's Principles of Internal Medicine, 22nd Edition (2025), McGraw Hill Medical - Chapters 65, 66, 67, 68, 69, and 70.*That is your complete Harrison's hematology master guide. Here is a summary of what was covered from each chapter:

What You Just Learned (Harrison's 22E, Section 9)

Chapter 65 - Interpreting Peripheral Blood Smears How to systematically examine platelets → RBCs → WBCs using oil immersion. Every abnormal morphology (Auer rods, schistocytes, Howell-Jolly bodies, Pelger-Hüet, tear-drops, etc.) with its clinical meaning. RDW formula and its use in separating iron deficiency from thalassemia.
Chapter 66 - Anemia and Polycythemia The three mechanisms of anemia (hypoproliferative, maturation defect, hemolysis/loss). EPO physiology. All iron studies with exact normal values. Megaloblastic vs microcytic workup. Myelophthisic (leukoerythroblastic) picture. Polycythemia vera vs secondary causes.
Chapter 67 - Disorders of Granulocytes and Monocytes Neutrophil life cycle, killing mechanisms (oxidative burst, NETs). Neutropenia classification. Hereditary neutropenia syndromes (Kostmann, WHIM, Shwachman-Diamond, Felty). CGD, LAD, Chediak-Higashi. Eosinophilia and basophilia differentials.
Chapter 68 - Primary and Secondary HLH HLH as hyperinflammatory convergent phenotype. Primary (genetic - perforin/PRF1 most common) vs secondary (EBV, T-cell lymphoma, MAS). HLH-2004 diagnostic criteria (5/8). Ferritin >10,000 = red flag. Treatment with dexamethasone + etoposide + HSCT for primary.
Chapter 69 - Bleeding and Thrombosis Mucosal bleeding = platelet/VWD vs hemarthroses = factor deficiency. Primary hemostasis defects (VWD, Bernard-Soulier, Glanzmann's). Coagulation cascade and what each test (PT, aPTT) measures. Inherited thrombophilias (Factor V Leiden most common). APS paradox (prolonged aPTT but causes clots).
Chapter 70 - Lymph Node and Spleen Enlargement Lymphadenopathy approach: <1% malignancy in primary care. Supraclavicular node = always investigate. When to biopsy. Massive splenomegaly differentials. Hypersplenism. Asplenic patient vaccination.
This is a shared conversation. Sign in to Orris to start your own chat.